Study identifier:D5890L00017
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A comparison of budesonide/formoterol Turbuhaler® 160/4.5 µg 2 inhalations BID plus as needed to budesonide Turbuhaler® 320 µg 2 inhalations BID plus terbutaline Turbuhaler® 0.4 mg as needed for the prevention of asthma relapse
asthma
Phase 3
No
Budesonide/formoterol
All
600
Interventional
18 Years - 65 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|